Cargando…
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
Elevated ribosome biogenesis in oncogene‐driven cancers is commonly targeted by DNA‐damaging cytotoxic drugs. Our previous first‐in‐human trial of CX‐5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA polymerase I (Pol I) transcription, revealed...
Autores principales: | Kusnadi, Eric P, Trigos, Anna S, Cullinane, Carleen, Goode, David L, Larsson, Ola, Devlin, Jennifer R, Chan, Keefe T, De Souza, David P, McConville, Malcolm J, McArthur, Grant A, Thomas, George, Sanij, Elaine, Poortinga, Gretchen, Hannan, Ross D, Hannan, Katherine M, Kang, Jian, Pearson, Richard B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604608/ https://www.ncbi.nlm.nih.gov/pubmed/32945574 http://dx.doi.org/10.15252/embj.2020105111 |
Ejemplares similares
-
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017) -
c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation
por: Poortinga, Gretchen, et al.
Publicado: (2011) -
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016) -
UBF levels determine the number of active ribosomal RNA genes in mammals
por: Sanij, Elaine, et al.
Publicado: (2008) -
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)